| scholarly article | Q13442814 |
| P356 | DOI | 10.5402/2012/710765 |
| P2093 | author name string | Anita C. Thomas | |
| P2860 | cites work | In-stent stenosis: pathology and implications for the development of drug eluting stents | Q24674571 |
| Incidence, predictors, and outcome of thrombosis after successful implantation of drug-eluting stents | Q28174787 | ||
| Local delivery of enoxaparin to decrease restenosis after stenting: results of initial multicenter trial: Polish-American Local Lovenox NIR Assessment study (The POLONIA study) | Q28174849 | ||
| S18886, a selective TP receptor antagonist, inhibits development of atherosclerosis in rabbits | Q28177053 | ||
| Platelet inhibition reduces cyclic flow variations and neointimal proliferation in normal and hypercholesterolemic-atherosclerotic canine coronary arteries | Q28191378 | ||
| Randomized study to assess the effectiveness of slow- and moderate-release polymer-based paclitaxel-eluting stents for coronary artery lesions | Q28191771 | ||
| Nitric oxide donating aspirins: novel drugs for the treatment of saphenous vein graft failure | Q28195868 | ||
| A randomized comparison of a sirolimus-eluting stent with a standard stent for coronary revascularization | Q28202763 | ||
| Physiological transport forces govern drug distribution for stent-based delivery | Q28209930 | ||
| Results of Prevention of REStenosis with Tranilast and its Outcomes (PRESTO) trial | Q28220325 | ||
| Safety of sirolimus-eluting stenting and its effect on restenosis in patients with unstable angina pectoris (a SIRIUS substudy) | Q28222362 | ||
| Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? | Q28240919 | ||
| Proteoglycans in atherosclerosis and restenosis: key roles for versican | Q28261672 | ||
| Liposomal Alendronate Inhibits Systemic Innate Immunity and Reduces In-Stent Neointimal Hyperplasia in Rabbits | Q42452499 | ||
| Local delivery of platelet-derived growth factor receptor-specific tyrphostin inhibits neointimal formation in rats | Q42484802 | ||
| Effectiveness of an antioxidant in preventing restenosis after percutaneous transluminal coronary angioplasty: the Probucol Angioplasty Restenosis Trial | Q42547365 | ||
| Periadventitial rapamycin-eluting microbeads promote vein graft disease in long-term pig vein-into-artery interposition grafts | Q43120643 | ||
| Suppression of neointimal thickening by a newly developed HMG-CoA reductase inhibitor, BAYw6228, and its inhibitory effect on vascular smooth muscle cell growth | Q43169653 | ||
| Effects of cilostazol on late lumen loss and repeat revascularization after Palmaz-Schatz coronary stent implantation | Q43514840 | ||
| Effects of lovastatin on progression of non-dilated and dilated coronary segments and on restenosis in patients after PTCA. The cholesterol lowering atherosclerosis PTCA trial (CLAPT). | Q43554122 | ||
| Randomised comparison of implantation of heparin-coated stents with balloon angioplasty in selected patients with coronary artery disease (Benestent II) | Q28281495 | ||
| The pathogenesis of atherosclerosis: a perspective for the 1990s | Q29547827 | ||
| Prevention of Cardiovascular Events and Death with Pravastatin in Patients with Coronary Heart Disease and a Broad Range of Initial Cholesterol Levels | Q29620696 | ||
| Usefulness of subcutaneous low molecular weight heparin (ardeparin) for reduction of restenosis after percutaneous transluminal coronary angioplasty | Q30304055 | ||
| Effect of thrombin inhibition with desulfatohirudin on early kinetics of cellular proliferation after balloon angioplasty in atherosclerotic rabbits | Q30468424 | ||
| Laser angioplasty of restenosed coronary stents: results of a multicenter surveillance trial. The Laser Angioplasty of Restenosed Stents (LARS) Investigators | Q30633025 | ||
| Restenosis: a challenge for pharmacology | Q30882943 | ||
| Differences in the effects of HMG-CoA reductase inhibitors on proliferation and viability of smooth muscle cells in culture | Q31396053 | ||
| HMG-CoA reductase inhibitors suppress maturation of human dendritic cells: new implications for atherosclerosis | Q33196578 | ||
| Clopidogrel | Q33500735 | ||
| Spatiotemporal controlled delivery of nanoparticles to injured vasculature | Q33529582 | ||
| Effect of controlled adventitial heparin delivery on smooth muscle cell proliferation following endothelial injury | Q33584566 | ||
| Strategies to achieve coronary arterial plaque stabilization | Q33643475 | ||
| Arterial remodeling in atherosclerosis, restenosis and after alteration of blood flow: potential mechanisms and clinical implications | Q33870084 | ||
| Targeted delivery of chemotherapeutics: tumor-activated prodrug therapy | Q33933206 | ||
| MRC/BHF Heart Protection Study of antioxidant vitamin supplementation in 20,536 high-risk individuals: a randomised placebo-controlled trial | Q33960122 | ||
| Arterial remodeling. Mechanisms and clinical implications | Q34023609 | ||
| Local delivery of dexamethasone for prevention of neointimal proliferation in a rat model of balloon angioplasty | Q34133379 | ||
| A prospective multicenter registry of laser therapy for degenerated saphenous vein graft stenosis: the COronary graft Results following Atherectomy with Laser (CORAL) trial | Q34190546 | ||
| Use of statins in CNS disorders | Q34300585 | ||
| Probucol prevents the progression of atherosclerosis in Watanabe heritable hyperlipidemic rabbit, an animal model for familial hypercholesterolemia | Q34340579 | ||
| The relative importance of arterial remodeling compared with intimal hyperplasia in lumen renarrowing after balloon angioplasty. A study in the normal rabbit and the hypercholesterolemic Yucatan micropig | Q34342627 | ||
| A randomized comparison of antiplatelet and anticoagulant therapy after the placement of coronary-artery stents | Q34374902 | ||
| Reducing bleeding complications after thrombolytic therapy for stroke: clinical potential of metalloproteinase inhibitors and spin trap agents | Q34432109 | ||
| Mechanisms of angioplasty and stent restenosis: implications for design of rational therapy | Q34453226 | ||
| Endothelin and restenosis | Q34484484 | ||
| Angiotensin-converting enzyme inhibition alters the fibrinolytic response to cardiopulmonary bypass | Q34543714 | ||
| A selective matrix metalloproteinase-12 inhibitor retards atherosclerotic plaque development in apolipoprotein E-knockout mice | Q34585560 | ||
| Gene therapy for restenosis: current status | Q34730698 | ||
| Potential emerging therapeutic strategies to prevent restenosis in the peripheral vasculature | Q34733613 | ||
| Rapamycin inhibits vascular smooth muscle cell migration | Q34736691 | ||
| Effects of local delivery of trapidil on neointima formation in a rabbit angioplasty model | Q35041906 | ||
| Neointima formed by arterial smooth muscle cells expressing versican variant V3 is resistant to lipid and macrophage accumulation | Q35069763 | ||
| Drug-eluting stents: potential applications for peripheral arterial occlusive disease | Q35083798 | ||
| Antibody-targeted drug delivery to injured arteries using layered double hydroxide nanoparticles. | Q50487524 | ||
| Antiproliferative agents alter vascular plasminogen activator inhibitor-1 expression: a potential prothrombotic mechanism of drug-eluting stents. | Q50705316 | ||
| Increased late mortality after sirolimus-eluting stents versus bare-metal stents in diseased saphenous vein grafts: results from the randomized DELAYED RRISC Trial. | Q50955757 | ||
| Perivascular paclitaxel wraps block arteriovenous graft stenosis in a pig model. | Q51168063 | ||
| Pathology of drug-eluting stents in humans: delayed healing and late thrombotic risk. | Q51170005 | ||
| Comparison of effectiveness and safety of drug-eluting stents versus vascular brachytherapy for saphenous vein graft in-stent restenosis. | Q51219610 | ||
| First human experience with angiopeptin-eluting stent: a quantitative coronary angiography and three-dimensional intravascular ultrasound study. | Q51343087 | ||
| Targeted delivery of heparin and LMWH using a fibrin antibody prevents restenosis. | Q51632656 | ||
| Locally delivered nanoencapsulated tyrphostin (AGL-2043) reduces neointima formation in balloon-injured rat carotid and stented porcine coronary arteries. | Q51640655 | ||
| Prolonged thrombin inhibition reduces restenosis after balloon angioplasty in porcine coronary arteries. | Q52529435 | ||
| Different response to balloon angioplasty of carotid and coronary arteries: effects on acute platelet deposition and intimal thickening. | Q52533099 | ||
| Disruption of graft endothelium correlates with early failure after off-pump coronary artery bypass surgery. | Q52564447 | ||
| Sympathoinhibitory responses to digitalis glycosides in heart failure patients. Direct evidence from sympathetic neural recordings. | Q54349860 | ||
| Endothelial cell injury in cardiovascular surgery: the intimal hyperplastic response. | Q55066900 | ||
| Platelet GPIIb-IIIa blockers | Q56944972 | ||
| Rapamune® (RAPA, rapamycin, sirolimus): mechanism of action immunosuppressive effect results from blockade of signal transduction and inhibition of cell cycle progression | Q57362835 | ||
| Final 5-Year Results of the TAXUS II Trial | Q58009440 | ||
| Replication in restenotic atherectomy tissue | Q58657458 | ||
| Carotid stenting and angioplasty: a statement for healthcare professionals from the Councils on Cardiovascular Radiology, Stroke, Cardio-Thoracic and Vascular Surgery, Epidemiology, and Prevention, and Clinical Cardiology, American Heart Association | Q43592729 | ||
| Stent-based delivery of sirolimus reduces neointimal formation in a porcine coronary model | Q43727885 | ||
| Sustained suppression of neointimal proliferation by sirolimus-eluting stents: one-year angiographic and intravascular ultrasound follow-up | Q43774893 | ||
| Tranilast inhibits transplant-associated coronary arteriosclerosis in a murine model of cardiac transplantation | Q43832381 | ||
| Novel nanocomposite stent coating releasing resveratrol and quercetin reduces neointimal hyperplasia and promotes re-endothelialization. | Q43864665 | ||
| The impact of tranilast on restenosis after coronary angioplasty: the Second Tranilast Restenosis Following Angioplasty Trial (TREAT-2). | Q43898419 | ||
| Pathological analysis of local delivery of paclitaxel via a polymer-coated stent | Q43978575 | ||
| Characteristics of intact and ruptured atherosclerotic plaques in brachiocephalic arteries of apolipoprotein E knockout mice | Q43989979 | ||
| Tranilast prevents activation of transforming growth factor-beta system, leukocyte accumulation, and neointimal growth in porcine coronary arteries after stenting | Q44030296 | ||
| Twenty-eight-day efficacy and phamacokinetics of the sirolimus-eluting stent | Q44072451 | ||
| Macrophage depletion by clodronate-containing liposomes reduces neointimal formation after balloon injury in rats and rabbits | Q44082556 | ||
| Ineffectiveness of colchicine for the prevention of restenosis after coronary angioplasty | Q44137235 | ||
| Inhibition of late vein graft neointima formation in human and porcine models by adenovirus-mediated overexpression of tissue inhibitor of metalloproteinase-3. | Q44157813 | ||
| Mechanism of late in-stent restenosis after implantation of a paclitaxel derivate-eluting polymer stent system in humans | Q44220790 | ||
| Trapidil in preventing restenosis after balloon angioplasty in the atherosclerotic rabbit | Q44222268 | ||
| Incidence, predictors, treatment, and long-term prognosis of patients with restenosis after drug-eluting stent implantation for unprotected left main coronary artery disease | Q44257328 | ||
| Enhanced extracellular matrix accumulation in restenosis of coronary arteries after stent deployment | Q44264755 | ||
| Statins inhibit secretion of metalloproteinases-1, -2, -3, and -9 from vascular smooth muscle cells and macrophages | Q44381124 | ||
| Antirestenotic effects of a locally delivered caspase inhibitor in a balloon injury model | Q44684882 | ||
| Rapamycin has no effect on fibrosis-associated gene expression or extracellular matrix accumulation when administered to animals with established or early allograft vasculopathy | Q44701822 | ||
| Catheter-based prostacyclin synthase gene transfer prevents in-stent restenosis in rabbit atheromatous arteries | Q44734198 | ||
| Local application of rapamycin inhibits neointimal hyperplasia in experimental vein grafts. | Q44864923 | ||
| Primary peripheral arterial stenoses and restenoses excised by transluminal atherectomy: a histopathologic study | Q44963784 | ||
| Tyrphostin AGL-2043 eluting stent reduces neointima formation in porcine coronary arteries. | Q45056895 | ||
| Conjugation of an antibody to cross-linked fibrin for targeted delivery of anti-restenotic drugs | Q45165068 | ||
| Four-year clinical follow-up of the rapamycin-eluting stent evaluated at Rotterdam Cardiology Hospital registry | Q45211629 | ||
| A prospective, single-blind, multicenter, dose escalation study of intracoronary iNOS lipoplex (CAR-MP583) gene therapy for the prevention of restenosis in patients with de novo or restenotic coronary artery lesion (REGENT I extension). | Q45865076 | ||
| Extracellular superoxide dismutase accelerates endothelial recovery and inhibits in-stent restenosis in stented atherosclerotic Watanabe heritable hyperlipidemic rabbit aorta. | Q45873445 | ||
| A randomized controlled trial of a paclitaxel-eluting stent versus a similar bare-metal stent in saphenous vein graft lesions the SOS (Stenting of Saphenous Vein Grafts) trial | Q46090655 | ||
| The restenosis paradigm revisited: an alternative proposal for cellular mechanisms | Q46465948 | ||
| Effectiveness of statin-eluting stent on early inflammatory response and neointimal thickness in a porcine coronary model | Q46622946 | ||
| Local and systemic delivery of low molecular weight heparin stimulates the reendothelialization after balloon angioplasty | Q47280987 | ||
| Vessel size, antioxidants, and restenosis: never too small, not too little, but often too late | Q47294488 | ||
| Effect of nadroparin, a low-molecular-weight heparin, on clinical and angiographic restenosis after coronary balloon angioplasty: the FACT study. Fraxiparine Angioplastie Coronaire Transluminale | Q47299271 | ||
| Time course of smooth muscle cell proliferation after local drug delivery of low-molecular-weight heparin using a porous balloon catheter | Q47306400 | ||
| Fish oils and low-molecular-weight heparin for the reduction of restenosis after percutaneous transluminal coronary angioplasty. The EMPAR Study | Q47324562 | ||
| Constrictive external nitinol meshes inhibit vein graft intimal hyperplasia in nonhuman primates | Q47336806 | ||
| Cellular trafficking of low molecular weight heparin incorporated in layered double hydroxide nanoparticles in rat vascular smooth muscle cells | Q47369990 | ||
| Low molecular weight heparin in prevention of restenosis after angioplasty. Results of Enoxaparin Restenosis (ERA) Trial | Q47371323 | ||
| Low molecular weight heparin (enoxaparin) reduces restenosis after iliac angioplasty in the hypercholesterolemic rabbit | Q47430660 | ||
| Enhanced effects of low molecular weight heparin intercalated with layered double hydroxide nanoparticles on rat vascular smooth muscle cells | Q47435197 | ||
| Native matrix metalloproteinase characteristics may influence early stenosis of venous versus arterial coronary artery bypass grafting conduits | Q47622922 | ||
| Differential expression and activity of matrix metalloproteinases during flow-modulated vein graft remodeling | Q47689201 | ||
| Neointimal tissue response at sites of coronary stenting in humans: macroscopic, histological, and immunohistochemical analyses | Q47713328 | ||
| Late thrombosis of paclitaxel-eluting stents: long-term incidence, clinical consequences, and risk factors in a cohort of 604 patients | Q47813915 | ||
| Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators | Q48661347 | ||
| Gene therapy for all aspects of vein-graft disease | Q35087837 | ||
| Pathology of the thin-cap fibroatheroma: a type of vulnerable plaque | Q35151273 | ||
| Tissue concentration of heparin, not administered dose, correlates with the biological response of injured arteries in vivo | Q35639977 | ||
| Gene therapy for ischemic cardiovascular diseases: some lessons learned from the first clinical trials | Q35982220 | ||
| Inhibition of tissue damage by the arachidonate lipoxygenase inhibitor BW755C | Q36259872 | ||
| Applications of nanotechnology to atherosclerosis, thrombosis, and vascular biology | Q36350939 | ||
| Narrative review: drug-eluting stents for the management of restenosis: a critical appraisal of the evidence. | Q36511835 | ||
| Current status of cardiovascular gene therapy | Q36823697 | ||
| Prospective, randomized, multicenter comparison of laser-facilitated balloon angioplasty versus stand-alone balloon angioplasty in patients with obstructive coronary artery disease. The Laser Angioplasty Versus Angioplasty (LAVA) Trial Investigators | Q36893705 | ||
| Conjugation of plasminogen activators and fibrin-specific antibodies to improve thrombolytic therapeutic agents | Q36954243 | ||
| Preventing restenosis after angioplasty: a multistage approach | Q37056663 | ||
| Drug-eluting stents - what should be improved? | Q37144221 | ||
| Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model | Q37221177 | ||
| Intramural delivery of rapamycin with alphavbeta3-targeted paramagnetic nanoparticles inhibits stenosis after balloon injury | Q37306731 | ||
| Delivery site of perivascular endothelial cell matrices determines control of stenosis in a porcine femoral stent model | Q37456910 | ||
| Frequency and severity of cyclic flow alternations and platelet aggregation predict the severity of neointimal proliferation following experimental coronary stenosis and endothelial injury | Q37632037 | ||
| Pharmacologic roles of heparin and glucocorticoids to prevent restenosis after coronary angioplasty. | Q37694212 | ||
| Colchicine and antineoplastic therapy for the prevention of restenosis after percutaneous coronary interventions | Q37694216 | ||
| Local drug delivery for treatment of coronary and peripheral artery disease | Q37765610 | ||
| Drug-eluting stents and balloons in peripheral arterial disease: evidence so far. | Q37874693 | ||
| Drug-eluting stent restenosis: effect of drug type, release kinetics, hemodynamics and coating strategy. | Q37972781 | ||
| Animal models for studying vein graft failure and therapeutic interventions | Q37979019 | ||
| Perivascular administration of drugs and genes as a means of reducing vein graft failure | Q37996741 | ||
| Surface modification of liposomes for selective cell targeting in cardiovascular drug delivery | Q38293409 | ||
| Biocompatibility aspects of new stent technology | Q38550109 | ||
| Perivascular delivery of a nitric oxide donor inhibits neointimal hyperplasia in vein grafts implanted in the arterial circulation | Q38552623 | ||
| Local delivery of biodegradable microparticles containing colchicine or a colchicine analogue: Effects on restenosis and implications for catheter-based drug delivery | Q38574692 | ||
| von Willebrand factor and platelet function | Q38687794 | ||
| Liposomal simvastatin attenuates neointimal hyperplasia in rats. | Q39770648 | ||
| Smooth muscle phenotypic changes in arterial wall homeostasis: implications for the pathogenesis of atherosclerosis | Q39816392 | ||
| Nanosuspensions of alendronate with gallium or gadolinium attenuate neointimal hyperplasia in rats. | Q40181870 | ||
| Local drug delivery for the prevention of restenosis. Fact, fancy, and future | Q40630968 | ||
| Inhibition of neointima formation after experimental coronary artery stenting: a new biodegradable stent coating releasing hirudin and the prostacyclin analogue iloprost | Q40772180 | ||
| Pharmacological approaches to the prevention of restenosis after coronary angioplasty | Q40836528 | ||
| Local drug delivery: current applications | Q40879706 | ||
| Role of intimal hyperplasia and arterial remodeling after balloon angioplasty: an experimental study in the atherosclerotic rabbit model | Q40949108 | ||
| Mechanisms and prevention of restenosis: from experimental models to clinical practice | Q41076451 | ||
| Pathophysiology and pharmacological approaches for prevention of coronary artery restenosis following coronary artery balloon angioplasty and related procedures | Q41364409 | ||
| Antioxidants and atherosclerotic heart disease | Q41548784 | ||
| Pharmacological approaches for the prevention of restenosis after percutaneous coronary intervention | Q41609837 | ||
| Local drug delivery systems and prevention of restenosis | Q41671783 | ||
| Aortocoronary saphenous vein graft disease: pathogenesis, predisposition, and prevention | Q41729196 | ||
| Randomized comparison of dexamethasone-eluting stents with bare metal stent implantation in patients with acute coronary syndrome: serial angiographic and sonographic analysis | Q42009826 | ||
| Contrasting effects of the intermittent and continuous administration of heparin in experimental restenosis | Q42287711 | ||
| P275 | copyright license | Creative Commons Attribution 3.0 Unported | Q14947546 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P304 | page(s) | 1-23 | |
| P577 | publication date | 2012-01-01 | |
| P1433 | published in | ISRN Vascular Medicine | Q50810579 |
| P1476 | title | Targeted Treatments for Restenosis and Vein Graft Disease | |
| P478 | volume | 2012 |
Search more.